In this phase III , randomized , double-blind , multicenter , 52-week study , the primary study end point was HbA1c change from baseline at week 26 in patients with renal impairment , as assessed with estimated glomerular filtration rate and categorized as mild , moderate , or severe ( 60 to 89 , 30 to 59 , and 15 to 29 mL/min/1 .73 m ( 2 ) , respectively ) .